How to Get Dayvigo (Lemborexant) in Rhode Island

What Is Dayvigo and Why Rhode Island Patients Are Asking About It

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for the treatment of insomnia in adults characterized by difficulty with sleep onset and/or sleep maintenance. Unlike older sedative-hypnotics such as zolpidem or benzodiazepines, lemborexant works by blocking orexin neuropeptides that promote wakefulness rather than broadly sedating the central nervous system.

In the SUNRISE-1 trial (N=1,006), lemborexant 5 mg and 10 mg both demonstrated statistically significant improvements in latency to persistent sleep compared with placebo and zolpidem extended-release 6.25 mg at one month. The 10 mg dose reduced sleep onset latency by approximately 10 minutes more than zolpidem ER, with fewer next-morning residual effects on postural stability. That favorable next-day profile matters in Rhode Island, where the state's older-than-average population (median age 40.2 per 2023 Census estimates) faces heightened fall risk from sedating sleep aids.

Rhode Island is among the smallest states by population, but its insomnia burden mirrors national patterns. The CDC's 2020 Behavioral Risk Factor Surveillance System found that roughly 14.5% of U.S. adults report trouble sleeping most days, and Rhode Island's rate tracks close to that figure. Access to newer, targeted insomnia therapies like lemborexant is a practical concern for the approximately 160,000 Rhode Islanders who may have chronic insomnia.

Telehealth Prescribing of Dayvigo in Rhode Island

Rhode Island permits licensed prescribers to prescribe Schedule IV controlled substances, including lemborexant, via telehealth. This is the fastest route for most patients.

The Ryan Haight Act historically required an in-person visit before a controlled substance could be prescribed via telemedicine. The DEA's 2023 proposed rulemaking and subsequent extensions have maintained flexibilities that allow Schedule III through V substances to be prescribed after a video evaluation, provided the prescriber holds a valid DEA registration and the patient is in a state where that prescriber is licensed. Rhode Island's Board of Medical Licensure and Discipline accepts interstate telehealth under the Interstate Medical Licensure Compact, of which Rhode Island is a member state.

What this means in practice: a Rhode Island resident can schedule a video visit with a sleep medicine physician or a general practitioner licensed in Rhode Island, receive an evaluation, and have a Dayvigo prescription sent electronically to a Rhode Island pharmacy. The entire process, from booking to receiving medication, can take as little as 2 to 5 business days.

Telehealth platforms that specialize in sleep disorders or insomnia management typically handle the prior authorization paperwork on behalf of the patient, which removes a common bottleneck. Patients should confirm that the platform's prescribers hold active Rhode Island licenses and DEA registrations before booking.

Who Can Prescribe Dayvigo in Rhode Island

Rhode Island authorizes several provider types to prescribe Schedule IV medications. Not just physicians.

MDs and DOs with active Rhode Island medical licenses and DEA registrations can prescribe lemborexant without supervision restrictions. Sleep specialists, psychiatrists, neurologists, and primary care physicians all commonly manage insomnia.

Advanced Practice Registered Nurses (APRNs) in Rhode Island have had full practice authority since 2017 under Rhode Island General Laws § 5-34-39. APRNs can evaluate, diagnose, and prescribe Schedule II through V substances independently, meaning an APRN can prescribe Dayvigo without physician co-signature. This significantly expands access, especially in areas outside Providence where physician availability is limited.

Physician Assistants (PAs) may prescribe Schedule IV medications under a collaborative agreement with a supervising physician. The agreement must be filed with the Rhode Island Department of Health. In practice, PAs in sleep clinics or primary care offices routinely write prescriptions for lemborexant under these agreements.

For patients uncertain about which provider type to see, the functional difference is minimal. Any of these three categories can order appropriate labs, write the prescription, and submit prior authorization documentation.

Prior Authorization: What Rhode Island Plans Require

Most Rhode Island insurers, including Medicaid, require prior authorization before covering Dayvigo. The process is straightforward when documentation is prepared in advance.

Rhode Island Medicaid (Neighborhood Health Plan of Rhode Island and fee-for-service) covers lemborexant with PA. Typical criteria include: a documented diagnosis of insomnia disorder (ICD-10 G47.00 or G47.01), failure of or contraindication to at least one first-line agent (usually generic zolpidem, eszopiclone, or trazodone), and confirmation that cognitive behavioral therapy for insomnia (CBT-I) was offered or attempted. The American Academy of Sleep Medicine's 2023 clinical practice guideline recommends CBT-I as first-line treatment, and many insurers reference this guideline when setting PA criteria.

Commercial plans (Blue Cross Blue Shield of Rhode Island, UnitedHealthcare, Aetna, Cigna) have similar step-therapy requirements. BCBSRI, the dominant commercial carrier in Rhode Island with approximately 39% market share, typically requires documentation of one failed generic sleep aid before approving Dayvigo.

Documentation checklist for PA submission:

• Chart notes confirming insomnia diagnosis and duration (typically 3+ months for chronic insomnia)
• Record of prior medication trials with dates, doses, and reasons for discontinuation
• Note addressing CBT-I discussion or referral
• Current medication list (to rule out drug interactions)
• Prescriber's clinical rationale for lemborexant specifically (e.g., fall risk concern with older sedatives, next-day impairment history)

Turnaround is usually 24 to 72 hours for electronic submissions. Rhode Island law requires insurers to respond to urgent PA requests within 24 hours. If a PA is denied, patients have the right to an expedited appeal, and the prescriber can request a peer-to-peer review with the plan's medical director.

Pharmacy Options in Rhode Island

Dayvigo prescriptions can be filled at any licensed Rhode Island pharmacy that stocks the medication. Patients have three main channels.

Retail pharmacies (CVS, Walgreens, Rite Aid, independent pharmacies) carry branded Dayvigo. As of mid-2026, no FDA-approved generic lemborexant exists. The brand-name cash price typically ranges from $380 to $420 for a 30-tablet supply, though Eisai's savings card can reduce commercially insured copays to as low as $0 for eligible patients.

Mail-order pharmacies approved by the patient's insurance plan can ship Dayvigo directly to a Rhode Island address. Express Scripts, CVS Caremark, and OptumRx all include Dayvigo on their formularies (subject to PA). Mail order often provides 90-day supplies at a lower per-unit cost.

503A compounding pharmacies licensed in Rhode Island can compound lemborexant preparations if a prescriber determines that a commercially available dosage form does not meet the patient's clinical needs (e.g., a patient who cannot swallow tablets and needs a liquid formulation). Rhode Island's Board of Pharmacy regulates 503A facilities under Rhode Island General Laws § 5-19.1, and these pharmacies must hold a current state license. Compounded preparations are not interchangeable with FDA-approved Dayvigo and are used only when clinically justified.

Clinical Considerations Before Starting Lemborexant

Before prescribing Dayvigo, Rhode Island clinicians should perform a focused evaluation. No specific laboratory panel is FDA-mandated for lemborexant initiation, but certain baseline assessments are standard practice.

Sleep history and screening tools. The Insomnia Severity Index (ISI) or Pittsburgh Sleep Quality Index (PSQI) provides a quantifiable baseline. A two-week sleep diary is recommended by the AASM to characterize sleep-wake patterns before pharmacotherapy.

Rule out secondary causes. Obstructive sleep apnea, restless legs syndrome, circadian rhythm disorders, and medication-induced insomnia should be excluded or addressed. The STOP-BANG questionnaire screens for sleep apnea risk. If the score is 5 or higher, polysomnography or home sleep testing is appropriate before starting any sedating agent.

Hepatic function. Lemborexant is metabolized primarily by CYP3A4 in the liver. The FDA prescribing information recommends a maximum dose of 5 mg in patients with moderate hepatic impairment (Child-Pugh B) and contraindicates the drug in severe hepatic impairment (Child-Pugh C). A basic metabolic panel and hepatic function tests are reasonable at baseline, particularly in patients with known liver disease or heavy alcohol use.

Drug interaction review. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) are contraindicated with lemborexant. Moderate inhibitors (fluconazole, erythromycin, diltiazem, grapefruit juice in large quantities) require dose reduction to 5 mg maximum. Rhode Island prescribers should review the patient's full medication list, including over-the-counter supplements, before writing the prescription.

Narcolepsy screening. DORAs are contraindicated in narcolepsy because blocking orexin signaling can worsen cataplexy and excessive daytime sleepiness. A brief screening for narcolepsy symptoms (cataplexy, sleep paralysis, hypnagogic hallucinations) is appropriate.

Dosing and What to Expect in the First Month

The standard starting dose is 5 mg taken once nightly, no more than 30 minutes before bedtime, with at least 7 hours of intended sleep remaining. The dose may be increased to 10 mg if 5 mg is well tolerated but insufficiently effective.

In SUNRISE-1, the 5 mg dose reduced subjective sleep onset latency (sSOL) by a mean of 16.4 minutes versus placebo at one month. The 10 mg dose reduced sSOL by 22.4 minutes. Wake after sleep onset (WASO) improved by 26.7 minutes with 5 mg and 30.0 minutes with 10 mg, both statistically significant (P<0.001 for each comparison).

The most common adverse effects in clinical trials were somnolence (reported in 7% at 5 mg, 10% at 10 mg), headache (6%), and abnormal dreams (2%). There were no signals of rebound insomnia upon discontinuation in the SUNRISE-2 extension study, which followed patients for 12 months. That finding is clinically relevant because rebound insomnia is a known limitation of benzodiazepine receptor agonists.

Patients should be counseled that the full benefit may take one to two weeks to become apparent, as orexin receptor antagonism produces gradual shifts in sleep architecture rather than the immediate sedation of a GABA-ergic agent. Sleep efficiency improvements tend to become more pronounced between weeks two and four.

Insurance and Cost Strategies for Rhode Island Residents

Without insurance, Dayvigo's retail cost is significant. Several strategies can reduce out-of-pocket expense for Rhode Island patients.

Eisai's DayvigoSavings.com program offers eligible commercially insured patients copay assistance. Patients with government insurance (Medicaid, Medicare, Tricare) are not eligible for manufacturer copay cards, per federal anti-kickback statute requirements.

Rhode Island Medicaid patients who receive approval through the PA process typically pay $0 to $3 per prescription, depending on their specific plan tier. Neighborhood Health Plan of Rhode Island, which covers the majority of Rhode Island's Medicaid population, lists Dayvigo on its specialty tier with PA.

Medicare Part D plans vary. Lemborexant sits on the specialty tier for most Part D formularies. Patients in the coverage gap ("donut hole") may face substantial costs, though the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective since 2025) limits maximum exposure. Rhode Island's SHIP (State Health Insurance Assistance Program) counselors can help Medicare beneficiaries compare Part D plans that include Dayvigo.

Patient assistance programs. Eisai offers the Eisai Patient Assistance Program for uninsured or underinsured patients who meet income criteria (typically below 400% of the federal poverty level). Applications are processed in approximately two weeks.

The SUNRISE-2 long-term extension study (Rosenberg et al., 2021) demonstrated consistent efficacy over 12 months with no dose escalation needed, which supports cost planning around a stable 5 mg or 10 mg regimen rather than escalating medication expenses over time.

Transferring a Dayvigo Prescription to Rhode Island

Patients relocating to Rhode Island or splitting time between states can transfer an existing Dayvigo prescription. Rhode Island law permits the transfer of Schedule IV prescriptions between pharmacies, including across state lines, provided both the sending and receiving pharmacies are licensed in their respective states and the prescription has remaining refills.

The process is simple. The patient contacts the new Rhode Island pharmacy, provides the name and location of the originating pharmacy, and the receiving pharmacist initiates the transfer. Electronic transfer is standard. For controlled substances, the DEA requires a one-time transfer (the original prescription cannot bounce between multiple pharmacies), and the transfer must be documented in both pharmacies' records.

If the original prescription has no remaining refills, the patient will need a new prescription from a Rhode Island-licensed provider. A telehealth visit with records from the prior prescriber can typically accomplish this within a few days.

Rhode Island-Specific Regulatory Notes

Rhode Island's Prescription Drug Monitoring Program (PDMP), administered through the Rhode Island Department of Health, requires prescribers to check the PDMP before issuing any Schedule II through IV prescription. This applies to lemborexant. The check is integrated into most electronic health record systems and adds minimal time to the visit.

Rhode Island also participates in PMP InterConnect, meaning prescribers can view PDMP data from neighboring states (Massachusetts, Connecticut). This is relevant for patients who may have received controlled substance prescriptions in nearby states.

The state has no special restrictions on DORAs beyond the standard Schedule IV requirements. There is no state-level quantity limit specific to lemborexant, though individual insurance plans may impose a 30-day supply limit per fill.